An NRP1/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy.
Yunjiang ZhouYaxin ChenYingying TanRong HuMiao-Miao NiuPublished in: Advanced healthcare materials (2021)
Supramolecular nanomedicines based on self-assembly of D-peptides have been of great interest as potential candidates for cancer therapy. Neuropilin-1 (NRP1) and mouse double minute 2 (MDM2) have been considered as the anticancer targets because of their overexpression in cancers. However, NRP1/MDM2-targeted D-peptide supramolecular nanomedicines remain unreported. Here, a potent anticancer D-peptide supramolecular nanomedicine targeting NRP1 and MDM2, termed as NMTP-5, is identified by using structure-based virtual screening techniques. NMTP-5 exhibits good biostability and strong cellular uptake performance. Moreover, NMTP-5 displays strong anticancer activity to SK-Hep-1 cells in vitro and in vivo, with no apparent host toxicity. This work demonstrates that NMTP-5 can be used as a potential chemotherapeutic agent for the treatment of liver cancer.
Keyphrases
- cancer therapy
- drug delivery
- water soluble
- energy transfer
- induced apoptosis
- oxidative stress
- cell cycle arrest
- cell proliferation
- magnetic resonance imaging
- transcription factor
- computed tomography
- signaling pathway
- cell death
- endoplasmic reticulum stress
- amino acid
- combination therapy
- climate change
- replacement therapy